About Ornithine transcarbamylase, mitochondrial
Ornithine transcarbamylase, mitochondrial (OTC) is a protein
from Homo sapiens identified by UniProt accession
P00480, 354 residues long.
MolForge cross-references it against 0 known binders and
419 disease associations.
Target properties
| Protein name | Ornithine transcarbamylase, mitochondrial |
|---|
| UniProt accession | P00480 |
|---|
| Gene | OTC |
|---|
| Organism | Homo sapiens |
|---|
| Length | 354 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (419)
Diseases linked to this target (Open Targets).
- Ornithine transcarbamylase deficiency · score 0.87
- genetic disorder · score 0.50
- Hyperammonemia · score 0.39
- Hypoammonemia · score 0.27
- lung adenocarcinoma · score 0.18
- squamous cell lung carcinoma · score 0.13
- Global developmental delay · score 0.12
- hypotrichosis simplex · score 0.10
- ringed hair disease · score 0.10
- Alopecia-intellectual disability syndrome · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P00480-F1 | alphafold | PREDICTED | 92.20 | — |
Amino-acid sequence (354 residues)
MLFNLRILLN NAAFRNGHNF MVRNFRCGQP LQNKVQLKGR DLLTLKNFTG EEIKYMLWLS ADLKFRIKQK GEYLPLLQGK SLGMIFEKRS TRTRLSTETG FALLGGHPCF LTTQDIHLGV NESLTDTARV LSSMADAVLA RVYKQSDLDT LAKEASIPII NGLSDLYHPI QILADYLTLQ EHYSSLKGLT LSWIGDGNNI LHSIMMSAAK FGMHLQAATP KGYEPDASVT KLAEQYAKEN GTKLLLTNDP LEAAHGGNVL ITDTWISMGQ EEEKKKRLQA FQGYQVTMKT AKVAASDWTF LHCLPRKPEE VDDEVFYSPR SLVFPEAENR KWTIMAVMVS LLTDYSPQLQ KPKF
Explore Ornithine transcarbamylase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets